Phosphoinositide 3-kinase targeting by the β galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death

Breast Cancer Research

Volumn 11, Issue 1, 2009, Pages

  Wells, Valerie ^a   Mallucci, Livio ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; CASPASE 3; CYTOKINE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PROTEIN KINASE B; RECOMBINANT BETA GALACTOSIDASE; UNCLASSIFIED DRUG; UO 126; GALECTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3,4,5-TRIPHOSPHATE; POLYPHOSPHOINOSITIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CELL; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER MORTALITY; CANCER THERAPY; CELL MEMBRANE; CELL PROLIFERATION; CELL STRAIN BT474; CELL STRAIN SKBR3; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFICACY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOPRECIPITATION; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; NORTHERN BLOTTING; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; BREAST TUMOR; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GALECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 4,5-DIPHOSPHATE; PHOSPHATIDYLINOSITOL PHOSPHATES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 67549095234     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2217     Document Type: Article

References (43)

1. Jarvinen TA, Liu ET. Simultaneous amplification of Her (ErbB2) and topoisomerase II α (TOP2A) genes in combination therapy in cancer. Curr Cancer Drug Targets 2006, 6:579-602. 10.2174/156800906778742497, 17100565.
2. Hynes NE, Stern DF. The biology of ErbB2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994, 1198:165-184.
3. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2 targeting strategies. Oncogene 2000, 19:6115-6121. 10.1038/sj.onc.1203972, 11156524.
4. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19:6550-6566. 10.1038/sj.onc.1204082, 11426640.
5. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER action in breast cancer. Oncogene 2000, 19:6102-6114. 10.1038/sj.onc.1203973, 11156523.
6. Segatto O, Lonardo F, Pierce JH, Bottaro DP, Di Fiore PP. The role of autophosphorylation in modulation of ErbB-2 transforming function. New Biol 1990, 2:187-195.
7. Dankart DL, Wang Z, Blackmore V, Moran MF, Muller WJ. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. Mol Cell Biol 1997, 17:5410-5425. 232391, 9271418.
8. Downward J. Targeting Ras signalling pathways in cancer therapy. Nat Rev Cancer 2003, 3:11-22. 10.1038/nrc969, 12509763.
9. Mitin N, Rossmann KL, Der CJ. Signaling interplay in Ras superfamily function. Curr Biol 2005, 15:R563-R574. 10.1016/j.cub.2005.07.010, 16051167.
10. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroek B, Gout I, Fry MJ, Waterfield MD, Downward J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994, 370:527-532. 10.1038/370527a0, 8052307.
11. Pacold ME, Suire S, Perisic O, Lara-Gonzales S, Davis CT, Walker EH, Hawkins PT, Stephens L, Eccleston JF, Williams RL. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase γ. Cell 2000, 103:931-943. 10.1016/S0092-8674(00)00196-3, 11136978.
12. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, Williams RO. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 2000, 6:909-919. 11090628, 10.1016/S1097-2765(05)00089-4.
13. Djordjevic S, Driscoll P. Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinase. Trends Biochem Sci 2002, 27:426-433. 10.1016/S0968-0004(02)02136-9, 12151228.
14. Downward J. PI3 kinase, Akt and cell survival. Semin Cell Dev Biol 2004, 15:177-182. 15209377, 10.1016/j.semcdb.2004.01.002.
15. Manning BD, Cantley LC. AKT/PKB signaling: navigation downstream. Cell 2007, 129:1261-1274. 10.1016/j.cell.2007.06.009, 17604717.
16. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2002, 2:489-501. 12094235, 10.1038/nrc839.
17. Luo JB, Manning D, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4:257-262. 10.1016/S1535-6108(03)00248-4, 14585353.
18. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/Akt pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4:988-1004. 16341064, 10.1038/nrd1902.
19. Stephens L, Williams R, Hawkins P. Phosphoinositide 3-kinase as a drug target in cancer. Curr Opin Pharmacol 2005, 5:357-365. 10.1016/j.coph.2005.03.002, 15963759.
20. Samuels Y, Wang Z, Bardelli A, Sillman N, Ptak J, Szabo S, Yan H, Gadzar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency mutations of the PIK3CA gene in human cancers. Science 2004, 304:554. 10.1126/science.1096502, 15016963.
21. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman Nszabo S, Buckhautts P, Farrell C, Meek P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park PH, Bachman KE, Papadopoulus N, Vogelsten B, Kinzler KW, Velculescu VE. The consensus coding sequence of human breast and colorectal cancers. Science 2006, 314:268-274. 10.1126/science.1133427, 16959974.
22. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 2006, 103:1475-1479. 1360603, 16432179, 10.1073/pnas.0510857103.
23. Samuels, Diaz LA, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lenqauer C, Kinzler RW, Vogelstein B, Velculescu VE. Mutant PIK3A promotes cell growth and invasion of human breast cancer cells. Cancer Cell 2005, 7:561-573. 10.1016/j.ccr.2005.05.014, 15950905.
24. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS. Breast-cancer associated PI3KCA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005, 65:10992-11000. 10.1158/0008-5472.CAN-05-2612, 16322248.
25. Miled N, Yan Y, Hong W-C, Perisic O, Zvelebil M, Inbar Y, Schneidman-Duhovny D, Wolfson HJ, Backer JM, Williams RL. Mechanism of two classes of cancer mutations in the phosphoinositide 3- kinase catalytic subunit. Science 2007, 317:239-242. 10.1126/science.1135394, 17626883.
26. Maehama T. PTEN: its derugulation and tumorigenesis. Biol Pharm Bull 2007, 30:1624-1627. 10.1248/bpb.30.1624, 17827710.
27. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, Waterfield MD, Ridley A, Downward J. Role of phosphoinositide-3-OH kinase in cell transformation and contol of the actin cytoskeleton by Ras. Cell 1997, 89:457-467. 10.1016/S0092-8674(00)80226-3, 9150145.
28. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA. Involvement of PI3K/Akt pathway in cell progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003, 17:590-603. 10.1038/sj.leu.2402824, 12646949.
29. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4:257-262. 10.1016/S1535-6108(03)00248-4, 14585353.
30. Wells V, Mallucci L. Identification of an autocrine negative growth factor: mouse β-galactoside binding protein is a cytostatic factor and a negative growth regulator. Cell 1991, 64:91-97. 10.1016/0092-8674(91)90211-G, 1986871.
31. Blaser C, Kaufman M, Muller C, Zimmermann C, Wells V, Mallucci L, Pircher H. β-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur J Immunol 1998, 28:2311-2319. 10.1002/(SICI)1521-4141(199808)28:08<2311::AID-IMMU2311>3.0.CO;2-G, 9710209.
32. Wells V, Downward J, Mallucci L. Functional inhibition of PI3K by the bGBP molecule suppresses Ras-MAPK signalling to block cell proliferation. Oncogene 2007, 26:7709-7714. 10.1038/sj.onc.1210580, 17603562.
33. Hynes NE, Gerber HA, Saurer S, Groner B. Overexpression of the c-ErbB2 protein in human breast tumor cell lines. J Cell Biochem 1989, 39:167-173. 10.1002/jcb.240390208, 2565909.
34. Soule HD, Maloney TM, Wolman SR, Peterson WD, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones F, Brooks FC. Isolation and characterisation of a spontaneously immortalised human breast epithelial cell line, MCF-10. Cancer Res 1990, 50:6075-6086.
35. Alberts B, Johnson A, Raff M, Roberts K, Walter P. Molecular biology of the cell 2002, 845-856. New York, NY: Garland Science.
36. Schulze A, Lehmann K, Jeffries HBJ, McMahon M, Downward J. Analysis of the transcriptional program induced by Ras in epithelial cells. Genes Dev 2001, 15:981-984. 312671, 11316792, 10.1101/gad.191101.
37. Karin M, Hunter T. Transcriptional control by protein phosphorylation;signal transmission from the cell surface to the nucleus. Curr Biol 1995, 5:747-757. 10.1016/S0960-9822(95)00151-5, 7583121.
38. Karanugaran D, Tzahar E, Beerli RR, Chen X, Graus-Porter D, Ratzkin BJ, Hynes NE, Yarden Y. ErbB2 is a common auxiliary subunit of NDF and EGF receptor: implication for breast cancer. EMBO J 1996, 15:254-264. 449940, 8617201.
39. Powis G, Bonjouklian R, Berggren MM, Gallegos A, Abrham R, Ashendel C, Zalkow L, Matter WF, Dodge J, Grindley G, Vlahos CJ. Wortmannin, a potent selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res 1994, 54:2419-2423.
40. Vlahos CJ, Matter WT, Hui KY, Brown F. A specific inhibitor of phosphatidyl-3-kinase,2-(morpholinyl)-8-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994, 269:5241-5248.
41. Wells V, Davies D, Mallucci L. Cell cycle arrest and induction of apoptosis by β galactoside binding protein (bGBP) in human mammary cancer cells. A potential new approach to cancer control. Eur J Cancer 1999, 35:978-983. 10.1016/S0959-8049(99)00020-9, 10533482.
42. Novelli F, Allione A, Wells V, Forni G, Mallucci L. Negative cell cycle control of humen T cells by β-galactoside binding protein (βGBP): induction of programmed cell death in leukaemic cells. J Cell Physiol 1999, 178:102-108. 10.1002/(SICI)1097-4652(199901)178:1<102::AID-JCP13>3.0.CO;2-6, 9886496.
43. Mallucci L, Wells V, Danikas A, Davies D. Turning cell cycle controller genes into cancer drugs. A role for an antiproliferative cytokine. Biochem Pharmacol 2003, 66:1563-1569. 10.1016/S0006-2952(03)00512-4, 14555235.